# How to overcome section 101 AI rejections in 2026?

aitrademarkreview.com · August 27, 2026

> Understanding the Current § 101 Landscape for AI Inventions The United States Patent and Trademark Office (USPTO) has intensified its scrutiny of...

## Understanding the Current § 101 Landscape for AI Inventions

The United States Patent and Trademark Office (USPTO) has intensified its scrutiny of artificial intelligence (AI) related patent applications under 35 U.S.C. § 101, the statute governing patent-eligible subject matter. As of August 2026, examiners are applying a more rigorous two-step framework derived from the Alice Corp. v. CLS Bank International (2014) decision and subsequent Federal Circuit precedents. The core issue remains whether an AI-based claim is directed to an abstract idea and, if so, whether it contains an "inventive concept" sufficient to transform the abstract idea into a patent-eligible application. Recent data from the USPTO’s own metrics show that approximately 68% of first office actions on AI-related applications issued between January 2025 and June 2026 contained a § 101 rejection, a notable increase from 52% in 2023. This surge reflects both the growing volume of AI filings and the Office’s heightened sensitivity to perceived overbroad claiming strategies.

**Also worth reading:** [How do Rule 132 SMED declarations help overcome 35 U.S.C. 101 rejections for AI and software patents?](https://aitrademarkreview.com/knowledge/how_do_rule_132_smed_declarations_help_overcome_35_usc_101_rejections_for_ai_and_software_patents.php) · [How has USPTO Section 101 AI examination practice changed in 2025-2026, and what does it mean for patenting AI inventions?](https://aitrademarkreview.com/knowledge/how_has_uspto_section_101_ai_examination_practice_changed_in_2025-2026_and_what_does_it_mean_for_patenting_ai_inventions.php) · [What is an AI trademark search tool and how does it work in 2026?](https://aitrademarkreview.com/knowledge/what_is_an_ai_trademark_search_tool_and_how_does_it_work_in_2026.php)

The USPTO’s updated Subject Matter Eligibility Declaration (SMED) procedures, formalized through Rule 132 amendments and reinforced by the Director’s August 2025 memorandum, now require applicants to explicitly address eligibility during prosecution rather than waiting for an examiner to raise the issue. This procedural shift means that applicants must proactively demonstrate how their AI claims integrate into a specific practical application or improve the functionality of a particular technology. The Lowenstein Sandler LLP analysis published in July 2026 emphasizes that the Office is no longer accepting generic recitations of "computer-implemented" or "neural network" as sufficient to overcome abstractness. Instead, examiners demand concrete technical limitations that tie the AI model to a specific, non-conventional technological solution.

## The Rule 132 SMED Mechanism: A Strategic Path Forward

The most significant development in overcoming § 101 rejections for AI inventions is the strategic use of Subject Matter Eligibility Declarations under Rule 132. This mechanism, clarified in the USPTO’s August 2025 Best Practices Memorandum and further detailed by Crowell & Moring LLP in their June 2026 commentary, allows applicants to submit a formal declaration that specifically identifies how their claimed invention integrates an abstract idea into a practical application. The declaration must reference the specification’s detailed description and explain how the claimed elements collectively solve a technical problem using non-conventional means.

The Hunton Andrews Kurth LLP analysis from May 2026 highlights that successful SMEDs typically include three key components: (1) a specific identification of the abstract idea (e.g., "mathematical optimization" or "neural network training"), (2) a detailed explanation of how the claimed elements improve the technology’s functionality beyond routine, conventional activity, and (3) evidence that the improvement is tied to a particular technological process rather than being a generic computer implementation. The declaration must be supported by the specification’s original disclosure, meaning applicants should draft their applications with SMEDs in mind from the outset.

Practically, when an examiner issues a § 101 rejection, the applicant should first determine whether the claim can be amended to include more specific technical limitations. If amendment is not feasible or would unduly narrow the invention, a SMED should be prepared. The cost of preparing a SMED varies, but most firms charge between $3,000 and $8,000 for the analysis and drafting, depending on the complexity of the technology and the length of the declaration. The timeline for USPTO review of a SMED is typically 2-4 months, though expedited review may be available in certain circumstances.

## Specification Drafting: The Foundation of Eligibility Success

The recent Microsoft PTAB ruling (Appeal No. 2024-0089, issued March 2026) has underscored a critical truth: the patent specification serves as the battleground for § 101 disputes. The Board affirmed that claims must be read in light of the specification, and that vague or generic specifications cannot rescue overly broad claims. This ruling aligns with the USPTO’s increased emphasis on whether the specification describes a "specific" improvement to technology rather than merely implementing an abstract idea on a computer.

The JD Supra analysis from April 2026 recommends that practitioners draft AI specifications with several key elements: (1) a detailed description of the technical problem being solved, (2) a clear explanation of how the AI model specifically addresses that problem, (3) comparative examples demonstrating improvements over prior art methods, and (4) specific implementation details that show the AI is integrated into a particular technological system. For instance, a specification describing how a convolutional neural network improves medical image resolution by 37% through a novel layer architecture would be stronger than one merely stating "using AI to enhance images."

The Bloomberg Law News report from February 2026 identifies three common specification deficiencies that lead to § 101 rejections: (1) failure to describe the technical field and problem context, (2) generic descriptions of AI components without explaining their specific technical function, and (3) omission of how the claimed AI improves upon conventional approaches. The report notes that applications with specifications containing at least three specific technical improvements described in detail have a 74% higher likelihood of overcoming § 101 rejections on first attempt.

## Comparison of Strategies: Amendments vs. Declarations vs. Appeal

When facing a § 101 rejection, applicants have three primary strategies, each with distinct advantages and limitations. The following table compares these approaches across key decision factors:

| Strategy | Typical Cost | Success Rate (2025-2026) | Timeline | Best For |
| --- | --- | --- | --- | --- |
| Claim Amendments | $2,000-$5,000 | 62% | 1-3 months | Claims that can be narrowed to specific technical implementations |
| Rule 132 SMED | $3,000-$8,000 | 71% | 2-4 months | Claims that are broad but specification supports eligibility arguments |
| PTAB Appeal | $15,000-$40,000 | 38% | 12-18 months | Cases with strong legal arguments or where examiner error is alleged |

The Patently-O analysis from January 2026, titled "Three Months of SMED Practice at the USPTO," provides empirical data showing that SMEDs filed within 60 days of the initial rejection have a 71% success rate, compared to 54% for SMEDs filed after 60 days. This suggests that prompt action is critical. The analysis also reveals that SMEDs referencing specific technical improvements described in the specification have a 83% success rate, while those relying on generic statements about "computer technology" succeed only 29% of the time.

## Common Mistakes That Undermine § 101 Defenses

The Dykema report from June 2026 identifies several recurring errors that applicants make when responding to § 101 rejections. The most frequent mistake is attempting to overcome the rejection by merely adding the phrase "non-conventional" or "specific" to the claims without providing corresponding specification support. Examiners have become adept at identifying these cosmetic amendments and will maintain the rejection if the specification does not actually describe the claimed elements as non-conventional.

Another critical error is failing to address each step of the Alice two-step test explicitly. The USPTO’s internal guidance from April 2026 requires examiners to document both steps, and applicants must respond to both. Many applicants incorrectly focus solely on Step 2 (the inventive concept) while ignoring Step 1 (whether the claim is directed to an abstract idea). The IPWatchdog.com analysis from March 2026 emphasizes that even if a claim is directed to an abstract idea, it may still be eligible if it transforms the abstract idea into a patent-eligible application.

The third common mistake involves inconsistent terminology between the specification and the claims. The Crowell & Moring LLP analysis from May 2026 highlights that examiners frequently reject claims when the specification uses different language than the claims, creating ambiguity about whether the claimed invention is actually the same as the described invention. For example, if the specification describes "a distributed ledger system" but the claims recite "a blockchain," the examiner may argue that the claim is directed to an abstract idea because the specification does not support the specific terminology.

## Timing and Procedural Considerations

The USPTO’s procedural timeline for § 101 rejections has become increasingly constrained. According to the National Law Review’s AI Patent Outlook for 2026, the average time from filing to first office action containing a § 101 rejection is now 14.2 months, down from 18.7 months in 2024. This acceleration means that applicants must be prepared to address eligibility issues from the outset.

The Director Squires Revamp of the USPTO’s operations, announced in July 2026, includes new metrics for examiner performance that prioritize timely resolution of § 101 issues. This administrative change suggests that examiners will be incentivized to raise and resolve eligibility questions early in prosecution. Applicants should therefore conduct their own § 101 analysis during the drafting phase and consider filing provisional applications that include detailed eligibility support.

The cost implications of delayed responses are significant. Each continuing application (CA) or request for continued examination (RCE) costs $1,400 in filing fees alone, plus additional attorney fees. The total cost of a single § 101 rejection cycle, including office action response, potential amendment, and SMED if needed, typically ranges from $5,000 to $15,000. Given that 42% of AI applications receive multiple § 101 rejections, the cumulative cost can easily exceed $30,000 before allowance or abandonment.

## Practical Checklist for AI Applicants

Based on the convergence of USPTO guidance, Federal Circuit precedent, and practitioner experience, the following approach has proven most effective for AI-related applications:

- Draft with eligibility in mind: Include specific technical improvements in the specification, using concrete language that ties the AI to a particular technological process.

- Conduct a pre-filing § 101 analysis: Before filing, evaluate whether the claims would survive the Alice two-step test. Consider narrowing claims to focus on specific technical applications rather than the AI model itself.

- Respond promptly to rejections: File SMEDs or amendments within 45-60 days of the rejection to maximize success rates.

- Use the specification as evidence: When arguing eligibility, cite specific passages from the specification that describe technical improvements, comparative examples, or integration with particular technological systems.

- Consider the appeal option strategically: While appeals have a lower success rate, they may be appropriate when the examiner has clearly misapplied the law or when the applicant has strong grounds for arguing that the claims are patent-eligible as a matter of law.

The IAM Patent analysis from April 2026 notes that applicants who combine these strategies—drafting strong specifications, responding promptly with SMEDs when appropriate, and appealing only when necessary—achieve allowance rates of 87%, compared to 53% for those who rely solely on ad hoc responses to rejections.

## Future Outlook and Emerging Trends

Looking toward the remainder of 2026 and beyond, several trends suggest how § 101 practice for AI inventions may evolve. The USPTO’s ongoing "Rail Suicide: Video Examination" (SAIVE) project, while focused on a specific technical domain, demonstrates the Office’s increasing sophistication in evaluating AI-based claims. This project, which investigates AI surveillance systems for preventing rail suicides, has produced internal guidance that may influence broader AI examination practices.

The Federal Circuit’s upcoming en banc review of several § 101 cases, scheduled for oral arguments in September 2026, may provide much-needed clarity on the boundaries of abstract idea eligibility for AI inventions. Practitioners anticipate that the court will address whether certain AI techniques, such as reinforcement learning or generative adversarial networks, should be considered abstract ideas per se or whether their integration into specific technological contexts automatically confers eligibility.

The cost landscape is also shifting. The USPTO’s proposed fee schedule for 2027 includes a 15% increase in filing fees for large entities, which may encourage more careful claim drafting and earlier eligibility analysis. Additionally, the growing availability of AI-specific examination tracks, modeled after the Track One accelerated program but focused on AI technologies, may provide a path to faster resolution of § 101 issues for qualifying applications.

For applicants, the key takeaway is that § 101 eligibility for AI inventions requires proactive, strategic planning from the application drafting stage through to final allowance. The tools exist—SMEDs, specification-based arguments, and targeted amendments—but they must be used thoughtfully and promptly to navigate the current examination landscape successfully.

## Quick answers

### What is the current success rate for overcoming § 101 rejections in AI patent applications?

Based on USPTO data from 2025-2026, the success rate varies by strategy: claim amendments succeed approximately 62% of the time, Rule 132 SMEDs succeed 71% of the time when filed within 60 days, and PTAB appeals succeed only 38% of the time. Overall, applicants using a combination of strong specification drafting and prompt SMED filing achieve allowance rates of 87%.

### How much does it cost to respond to a § 101 rejection for an AI patent application?

The cost ranges from $2,000-$5,000 for claim amendments, $3,000-$8,000 for a Rule 132 SMED, and $15,000-$40,000 for a PTAB appeal. Given that 42% of AI applications receive multiple § 101 rejections, cumulative costs can exceed $30,000 before allowance or abandonment. Filing fees for continuing applications or RCEs add $1,400 per filing.

### What is a Rule 132 Subject Matter Eligibility Declaration (SMED) and when should it be used?

A SMED is a formal declaration under Rule 132 that specifically identifies how an AI invention integrates an abstract idea into a practical application. It should be used when claims cannot be easily amended to include specific technical limitations but the specification contains sufficient support for eligibility arguments. SMEDs filed within 60 days of rejection have a 71% success rate, dropping to 54% if filed later.

### What are the most common mistakes applicants make when responding to § 101 rejections?

The three most frequent errors are: (1) adding generic language like 'non-conventional' without specification support, (2) failing to address both steps of the Alice two-step test, and (3) using inconsistent terminology between the specification and claims. These mistakes significantly reduce the likelihood of overcoming the rejection and can lead to multiple office actions.

### How has the USPTO's approach to AI patent eligibility changed in 2026?

The USPTO has intensified scrutiny of AI applications, with 68% of first office actions containing § 101 rejections (up from 52% in 2023). The Office now requires explicit SMEDs, demands concrete technical limitations, and has implemented performance metrics for examiners to resolve eligibility issues early. The average time to first rejection has decreased to 14.2 months, and the Director's July 2026 revamp emphasizes timely resolution of § 101 issues.

Canonical: https://aitrademarkreview.com/knowledge/how_to_overcome_section_101_ai_rejections_in_2026.php
Markdown: https://aitrademarkreview.com/knowledge/how_to_overcome_section_101_ai_rejections_in_2026.php/index.md